- Home
- CAST vs ALEC Comparison
CAST vs ALEC Comparison
Compare CAST & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAST | ALEC |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.3M | 167.6M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CAST | ALEC |
|---|---|---|
| Price | $1.33 | $2.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $6.00 | $4.83 |
| AVG Volume (30 Days) | ★ 8.1M | 1.5M |
| Earning Date | 06-26-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $21,045,000.00 |
| Revenue This Year | N/A | $2.03 |
| Revenue Next Year | N/A | $29.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.50 | $1.09 |
| 52 Week High | $12.20 | $3.40 |
Technical Indicators
Market Signals| Indicator | CAST | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 43.28 | 61.69 |
| Support Level | $0.67 | $1.93 |
| Resistance Level | $1.99 | $2.58 |
| Average True Range (ATR) | 0.34 | 0.21 |
| MACD | 0.08 | 0.03 |
| Stochastic Oscillator | 32.05 | 78.86 |
Price Performance
Historical ComparisonAbout CAST FreeCast Inc. Class A Common Stock
FreeCast Inc is a streaming technology company that provides platform-as-a-service solutions for television and digital video distribution. Its platform infrastructure supports telecom operators, internet service providers, broadcasters, municipalities, utilities, brands, and device manufacturers in deploying and managing digital media and streaming services.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.